Protamine—The Journey from DNA to Heparin Neutralization to Gene therapy

Abstract

Protamine is now well recognized as a key heparin neutralizing agent. However, protamine was discovered over a century ago, during experiments performed to uncover the secrets behind heritability. Although protamine was discovered as a highly charged protein, it did not receive the attention it deserved until the dawn of insulin era, when it was used to create the neutral protamine Hagedorn formulation. Based on the same principles, protamine was identified to neutralize heparin and has since been used successfully for many years in cardiothoracic surgery. More recently, its clinical applications have extended to gene therapy. In this historical sketch, the journey from the discovery of protamine, onwards to heparin neutralization, and up to its utilization in genetic modulatory treatments is detailed.

Keywords

DNA - gene therapy - heparin - insulin - protamine

Publication History

Article published online:
02 November 2021

• References

• 1 Holterhoff K. The history and reception of Charles Darwin's hypothesis of pangenesis. J Hist Biol 2014; 47 (04) 661-695
• 2 Liu Y. Darwin's pangenesis and medical genetics. Adv Genet 2018; 102: 67-92
• 3 Schwartz J. In Pursuit of the Gene: From Darwin to DNA. Boston: Harvard University Press; 2009
• 4 Griffiths AJF, Miller JH, Suzuki DT. et al. An Introduction to Genetic Analysis. 7th edition.. New York: W. H. Freeman; 2000
• 5 Sandler I. The re-examination of Spallanzani's interpretation of the role of the spermatic animalcules in fertilization. J Hist Biol 1973; 6: 193-223
• 6 Lane N. The unseen world: reflections on Leeuwenhoek (1677) 'Concerning little animals'. Philos Trans R Soc Lond B Biol Sci 2015; 370 (1666): 20140344
• 7 Harris H. The Birth of the Cell. Connecticut: Yale University Press; 2000: 76
• 8 Dahm R. From discovering to understanding. Friedrich Miescher's attempts to uncover the function of DNA. EMBO Rep 2010; 11 (03) 153-160
• 9 Dahm R. Friedrich Miescher and the discovery of DNA. Dev Biol 2005; 278 (02) 274-288
• 10 Mirsky AE. The discovery of DNA. Sci Am 1968; 218 (06) 78-88
• 11 Greenstein JP. Friedrich Miescher, 1844–1895. Sci Mon 1943; 57: 523-532
• 12 Oxford English Dictionary online edition. Accessed September 27, 2021 at: https://www-oed-com.manchester.idm.oclc.org/view/Entry/153108?redirectedFrom=protamine#eid
• 13 Ando T, Yamasaki M, Suzuki K. Protamines. Isolation, characterization, structure and function. Mol Biol Biochem Biophys 1973; 12 (00) 1-114
• 14 Ruseska I, Fresacher K, Petschacher C, Zimmer A. Use of protamine in nanopharmaceuticals—a review. Nanomaterials (Basel) 2021; 11 (06) 1508
• 15 Novo Nordisk foundation History online. Accessed September 27, 2021 at: https://novonordiskfonden.dk/en/about-the-foundation/history/
• 16 Felig P. Landmark perspective: protamine insulin. Hagedorn's pioneering contribution to drug delivery in the management of diabetes. JAMA 1984; 251 (03) 393-396
• 17 Leyton O. The administration of insulin in suspension. Lancet 1929; 1: 756-759
• 18 Hagedorn HC, Jensen BN, Krarup NB, Wodstrup I. Landmark article Jan 18, 1936: Protamine insulinate. By H.C. Hagedorn, B.N. Jensen, N.B. Krarup, and I. Wodstrup. JAMA 1984; 251 (03) 389-392
• 19 Hagedorn HC. Protamine insulinate: (section of therapeutics and pharmacology). Proc R Soc Med 1937; 30 (06) 805-814
• 20 Chargaff E, Olson KB. Studies on the chemistry of blood coagulation: VI. Studies on the action of heparin and other anticoagulants: the influence of protamine on the anticoagulant effect in vivo. J Biol Chem 1937; 122: 153-167
• 21 Jorpes E, Edman P, Thaning T. Neutralisation of action of heparin by protamine. Lancet 1939; 2: 975-976
• 22 Jarzebska NT, Mellett M, Frei J, Kündig TM, Pascolo S. Protamine-based strategies for RNA transfection. Pharmaceutics 2021; 13 (06) 877
• 23 Amos H. Protamine enhancement of RNA uptake by cultured chick cells. Biochem Biophys Res Commun 1961; 5 (01) 1-4
• 24 McMillan RB, Kuntz VD, Devenica LM, Bediako H, Carter AR. DNA looping by protamine follows a nonuniform spatial distribution. Biophys J 2021; 120 (12) 2521-2531
• 25 Grijalvo S, Puras G, Zárate J. et al. Cationic niosomes as non-viral vehicles for nucleic acids: challenges and opportunities in gene delivery. Pharmaceutics 2019; 11 (02) 50
• 26 Sorgi FL, Bhattacharya S, Huang L. Protamine sulfate enhances lipid-mediated gene transfer. Gene Ther 1997; 4 (09) 961-968